![]() MERS-CoV can have devastating consequences in 2015, one person infected with MERS-CoV returned to South Korea from the Middle East, subsequently spreading the virus to 186 people, resulting in the death of 36, and causing substantial socioeconomic disruption. Large outbreaks have also occurred outside the Middle East. About 80% of human cases have been reported in Saudi Arabia. Since it was first identified in Saudi Arabia in 2012, 2229 laboratory-confirmed cases of MERS-CoV have occurred in 27 countries. No vaccine against MERS-CoV is currently available. ![]() Approximately 35% of reported patients with MERS-CoV have died. Infection can cause respiratory disease including fever and a cough that can progress into severe pneumonia. Should CEPI exercise its option to provide support for further clinical development, Oxford will undertake phase 2 testing of the vaccine, in partnership with the King Abdullah International Medical Research Centre (KAIMRC) in Riyadh, Kingdom of Saudi Arabia, and the Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme at Kilifi, Kenya.Īs part of the collaboration, CEPI will also provide funding of up to $2.1 million to support the preclinical development of a Lassa vaccine and up to $2.0 million to support the preclinical development of a Nipah vaccine.įirst identified in 2012, MERS-CoV is carried by camels and spread by droplet infection of the airways. Janssen’s proprietary vaccine-manufacturing platform will enable rapid and efficient production of large volumes of vaccines. Dependent on phase 1 results, CEPI will have the option to provide additional investment for a phase 2 trial and manufacture of an investigational vaccine stockpile that would be available for use in the event of an outbreak. Under the terms of the Framework Partnering Agreement for the collaboration, Oxford and Janssen will receive $14.6 million from CEPI to support manufacturing of a phase 2 batch and preparation for stockpiling of a MERS-CoV vaccine candidate. ![]() Oxford has already initiated clinical development of the MERS-CoV vaccine, with funding from the UK Department of Health and Social Care, and a phase 1 clinical trial of the vaccine is underway in the UK. Preclinical development of novel vaccines against Lassa and Nipah viruses will also be undertaken as part of this collaboration. ![]() CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a collaboration with The Jenner Institute at the University of Oxford and Janssen Vaccines & Prevention B.V.-part of the Janssen Pharmaceutical Companies of Johnson & Johnson-through which they will receive funding to advance the development and manufacture of a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV). ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |